Halozyme Therapeutics Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $907.5M | $1.10B | $118.7M |
| FY2022 | $1.67B | $1.84B | $234.2M |
| FY2023 | $1.65B | $1.73B | $118.4M |
| FY2024 | $1.70B | $2.06B | $115.9M |
| FY2025 | $2.48B | $2.53B | $133.8M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2021 | $907.5M | $1.10B | $118.7M |
| FY2022 | $1.67B | $1.84B | $234.2M |
| FY2023 | $1.65B | $1.73B | $118.4M |
| FY2024 | $1.70B | $2.06B | $115.9M |
| FY2025 | $2.48B | $2.53B | $133.8M |